Key result
Omega-3 fatty acids had no significant overall effect on preventing atrial fibrillation recurrences after cardioversion (OR 0.63; 95% CI 0.35-1.13; p=0.12).
Why the study?
Does omega-3 fatty acids prevent atrial fibrillation recurrences after cardioversion in human subjects?
Meta-Analysis
Does omega-3 fatty acids prevent atrial fibrillation recurrences after cardioversion in human subjects?
While omega-3 fatty acids overall do not significantly prevent atrial fibrillation recurrence after cardioversion, initiating therapy at least 4 weeks prior to the procedure may offer significant benefit.
Answers are grounded in this paper and cite their sources.
Does not support omega-3 use to prevent atrial fibrillation recurrence after cardioversion; confirms overall lack of efficacy.
BACKGROUND: Previous randomized studies have reported conflicting results on the efficacy of omega-3 fatty acids in preventing atrial fibrillation (AF) recurrences after cardioversion. OBJECTIVE: A systematic review and meta-analysis of the role of omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion was conducted. METHODS: PubMed, Cochrane Library, Elsevier, Science Online database were searched up to the end of January 2012 to identify all of the studies in human subjects that reported the effects of omega-3 fatty acids on the prevention of atrial fibrillation recurrences after cardioversion. RESULTS: Overall, omega-3 fatty acids had no significant effect on the prevention of AF recurrences after cardioversion (OR: 0.63,95% CI 0.35-1.13; p=0.12). The heterogeneity among the studies was significant (p=0.01, I(2)=66%). Subgroup analysis showed that by administering omega-3 fatty acids at least 4 weeks prior to cardioversion and continuing thereafter, the recurrence rate of AF is significantly low (OR: 0.39, 95% CI 0.25-0.61; p<0.0001). CONCLUSION: In the subgroup administered omega-3 fatty acids at least 4 weeks prior to cardioversion and continued thereafter, the recurrence rate of AF was significantly low. More double-blind, randomized, placebo-controlled, multicenter studies with high quality and longer follow-up periods are needed to affirm our conclusion.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2012) conducted a meta-analysis in Atrial fibrillation. Omega-3 fatty acids was evaluated on Atrial fibrillation recurrences after cardioversion (OR 0.63, 95% CI 0.35-1.13, p=0.12). Omega-3 fatty acids had no significant overall effect on preventing atrial fibrillation recurrences after cardioversion (OR 0.63; 95% CI 0.35-1.13; p=0.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: